Education
About Us
Working with TipRanks
Follow Us
Vaxcyte, Inc. (PCVX)
:PCVX
Earnings Data
Report Date
May 12, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-1.04Last Year’s EPS
-0.85Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 25, 2025
|% Change Since: -6.88%
|Next Earnings Date:May 12, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted Vaxcyte's strong financial position, significant clinical and manufacturing progress, and proactive regulatory engagement. However, challenges include increased expenses, potential regulatory uncertainties, and the need to meet non-inferiority criteria in clinical studies. Vaxcyte remains optimistic about its pipeline and future growth.Company Guidance
During the Vaxcyte fourth quarter and full year 2024 earnings call, key guidance was provided on the company's financial and operational outlook. As of December 31, 2024, Vaxcyte reported a strong financial position with $3.13 billion in cash, cash equivalents, and investments. The company anticipates significant increases in R&D and G&A expenses in 2025, primarily driven by manufacturing investments for the VAX-31 adult Phase 3 clinical program and the growth in personnel. Vaxcyte's dedicated manufacturing suite at Lonza is on track to be completed by early 2025, with $127.8 million in additional capital expenditures in 2024, bringing the total project cost to $214.3 million. Operationally, the company is advancing its PCV franchise, with the VAX-31 adult Phase 3 pivotal study expected to initiate by mid-2025 and top-line data anticipated in 2026. Additionally, Vaxcyte is progressing its VAX-24 and VAX-31 infant programs, with the first key dataset for VAX-31 expected by mid-2026. These efforts are supported by a robust pipeline aimed at addressing bacterial threats and antimicrobial resistance, ensuring Vaxcyte is well-prepared for sustainable growth and future vaccine launches.Strong Financial Position
Vaxcyte ended 2024 with $3.13 billion in cash, cash equivalents, and investments, bolstered by $2.2 billion from successful equity offerings.
VAX-31 Clinical Success
VAX-31 showed strong Phase 1/2 results in adults, leading to its advancement to Phase 3, with Breakthrough Therapy Designation granted by the FDA.
Manufacturing Expansion
Vaxcyte is building a dedicated manufacturing suite with Lonza, on track for completion by early next year, supporting future global supply.
Progress in Early-Stage Vaccine Candidates
Vaxcyte continues to advance vaccine candidates against AMR threats, including VAX-A1 for Group A Strep.
Regulatory Engagement
Vaxcyte established a public affairs function, enhancing engagement with policymakers to support vaccine innovation.
---
PCVX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PCVX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 25, 2025 | $79.35 | $78.65 | -0.88% |
| Nov 05, 2024 | $107.56 | $104.07 | -3.24% |
| Aug 06, 2024 | $73.93 | $70.52 | -4.61% |
| May 08, 2024 | $66.79 | $65.57 | -1.83% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Vaxcyte, Inc. (PCVX) report earnings?
Vaxcyte, Inc. (PCVX) is schdueled to report earning on May 12, 2025, TBA Not Confirmed.
What is Vaxcyte, Inc. (PCVX) earnings time?
Vaxcyte, Inc. (PCVX) earnings time is at May 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PCVX EPS forecast?
PCVX EPS forecast for the fiscal quarter 2025 (Q1) is -1.04.
---